Lonza’s mission impossible: Supplying the world with mRNA vaccines
At the beginning of 2020, a few weeks before COVID-19 was declared a global pandemic, André Goerke, the Head of Value Chain Management at Lonza – a leading pharmaceutical contract development and manufacturing company based in Switzerland – had just completed the merger of two global business units into a new biotech business unit of the company. After returning from a wonderful day of snowboarding, André received a phone call from his friend Juan Andres that would change his professional focus for the next two years. Juan had become the Head of Technical Operations at the US biotech start-up Moderna – which was working on various early-stage drugs using the novel mRNA technology. The world had been watching with sorrow as cases of COVID-19 appeared in Europe, and stock markets across the globe were in free fall. After learning of these mounting concerns about a pandemic, Moderna had immediately started sequencing the COVID-19 virus. It was convinced that it had an effective and safe mRNA sequence that could serve as a vaccine against the virus. But it had not been able to manufacture anywhere near the volume necessary to fight a global pandemic. Hence, Juan asked André if Lonza could set up a global supply chain and be Moderna’s active ingredient partner to manufacture hundreds of millions of mRNA vaccine doses a year. André sensed that this was an incredible opportunity, but there were several risks involved, including counterparty, technology, legal, regulatory, supply chain and HR risks. From multiple angles, this looked like a mission impossible for Lonza, especially since manufacturing was expected to start by the end of 2020.
- How to make far-reaching strategic decisions with imperfect information at hand.
- Lessons on organizational design, customer centricity and the adaptive strategy approach.
- The importance of leadership with purpose and corporate culture in steering companies through phases of disruptive transformation.
Lonza Group, Manufacturing, Biotechnology, Healthcare, Healthcare, Pharmaceuticals
2020-2022
Cranfield University
Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]
Harvard Business School Publishing
60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]
NUCB Business School
1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
Assortment optimization presents a complex challenge for retailers, as it depends on numerous decision factors. Changes in assortment can result in demand redistribution with multi-layered consequences. This complexity is even more pronounced for ...
The rapid advancement of generative artificial intelligence (GenAI) is unprecedented. Looking ahead at the job markets of 2030 and beyond, we can forecast the types of jobs and skills that may get automated. Alternatively, we can also see which ne...
Shenzhen Power-Solution (SPS), founded in 2009 in China as an entrepreneurial venture, disrupted traditional lighting markets in African villages with its flagship product, Candles Killer. This solar lamp, priced under $5, replaces hazardous keros...
On 12 May 2025, China and the United States released a joint statement that ended the recent escalation in tariffs. For 90 days each agreed to lower their tariffs by 115%. This only applies to import taxes imposed since 2 April 2025—all prior tari...
This note provides a comprehensive framework for understanding and developing the core interpersonal processes essential for effective leadership. It identifies and explores seven key processes: Communication, Visioning, Alliance Building, Persuas...
This note presents a comprehensive framework for improving decision-making capabilities in high-pressure, high-stakes environments. It introduces six evidence-based strategies that help leaders maintain clarity, focus and effectiveness when facing...
Purpose Jean Boddewyn’s (1929–2022) work in international business political behavior launched a stream of research at the intersection of international business (IB) and strategic management that is now referred to as international nonmarket str...
in European Journal of Operational Research August 2025, vol. 324, no. 3, pp. 799-813, https://doi.org/10.1016/j.ejor.2025.01.035
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in Multinational Business Review 6 May 2025, ePub before print, https://doi.org/10.1108/MBR-10-2024-0201
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications